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Abstract
The Epstein-Barr virus (EBV) encoded nuclear antigen (EBNA)-1 regulates virus replication and transcription, and participates
in the remodeling of the cellular environment that accompanies EBV induced B-cell immortalization and malignant
transformation. The putative cellular targets of these effects of EBNA-1 are largely unknown. To address this issue we have
profiled the transcriptional changes induced by short- and long-term expression of EBNA-1 in the EBV negative B-cell
lymphoma BJAB. Three hundred and nineteen cellular genes were regulated in a conditional transfectant shortly after EBNA-
1 induction while a ten fold higher number of genes was regulated upon continuous EBNA-1 expression. Promoter analysis
of the differentially regulated genes demonstrated a significant enrichment of putative EBNA-1 binding sites suggesting
that EBNA-1 may directly influence the transcription of a subset of genes. Gene ontology analysis of forty seven genes that
were consistently regulated independently on the time of EBNA-1 expression revealed an unexpected enrichment of genes
involved in the maintenance of chromatin architecture. The interaction network of the affected gene products suggests that
EBNA-1 may promote a broad rearrangement of the cellular transcription landscape by altering the expression of key
components of chromatin remodeling complexes.
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Introduction
Epstein-Barr virus (EBV) is a gamma herpes virus that infects
the majority of human adults. Like other herpes viruses, EBV has
a dual life cycle characterized by the establishment of latency in B-
lymphocytes and productive infection in epithelial cells [1,2].
Latently infected B-cells express a restricted set of viral genes that
promote a global rearrangement of the cellular environment,
leading to B-cell growth transformation and immortalization [2,3].
Reprogramming of cell proliferation and apoptosis and deregula-
tion of genome integrity maintenance machineries are likely to
underlie the association of EBV with a variety of malignancies,
including virtually all cases of endemic Burkitt’s lymphoma (BL)
and nasopharyngeal carcinoma (NPC) and approximately half of
Hodgkin’s lymphomas (HL) [1,4]. These proliferating cells express
distinct subsets of latency genes that define viral programs, known
as latency I, II and III, whose common denominator is the regular
expression of the EBV nuclear antigen (EBNA)-1.
EBNA-1 is required for the correct partitioning of viral
episomes during cell division [5,6] and regulates the activity of
viral promoters. Hence, binding of EBNA-1 to the family-of-
repeats (FR) locus in the latent origin of replication, oriP, positively
regulates the expression of the Cp promoter that drives the
transcription of six EBNA genes in cells expressing latency III [7,8]
while binding to specific sites in the Qp promoter is involved in the
autoregulation of EBNA-1 expression in different latency types [9].
EBNA-1 binds also to cellular DNA, although with a lower affinity
compared to viral DNA [10]. A set of EBNA-1 binding sites was
recently characterized in the human genome using chromatin
immunoprecipitation and a microarray of human promoter
sequences [11]. Surprisingly several promoters containing
EBNA-1 binding sites were not regulated by EBNA-1 in luciferase
reporter assays [12] suggesting that additional transcription
factors, or the chromatin architecture in which transcription
occurs, may influence the effect of EBNA-1. Thus, while the
capacity of EBNA-1 to act as a transcription regulator may
contribute to reshape the cellular environment during EBV
infection and malignant transformation, the primary and second-
ary targets of this effect remain unknown.
Gene expression profiling has been used to dissect the influence of
EBNA-1 on cellular transcription. By mining public gene expression
databases of EBV positive B-cell lines expressing different types of
latency we have identified the gene encoding for the catalytic subunit
of the NADPH oxidase NOX2 as a transcriptional target of EBNA-1
whose upregulation may be involved in the induction of DNA
damage and genomic instability in lymphoid malignancies [13].
Stable or transient transfection of EBNA-1 was shown to affect the
expression of a range of cellular genes in NPC and HD models,
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signaling [14,15]. Validation of a subset of the regulated genes
revealed that EBNA-1 enhances the activity of transcription factors,
including STAT1, AP1, c-Jun and ATF2 and regulates a variety of
cellular processes including TGF-b signaling, cytokine production
and angiogenesis [15,16]. The mechanisms by which EBNA-1 exerts
such pleyotropic effect on a wide variety of diverse cellular processes
remains, however, unclear.
We have addressed this issue by comparing the transcription
profiles of stable and conditional EBNA-1 transfected sublines of
the EBV negative B-cell lymphoma BJAB where EBNA-1 was
expressed for few days, few months or several years. Our data
suggest that, while exerting a direct effect on a subset of the
regulated genes, EBNA-1 may orchestrate a broad rearrangement
of transcription by regulating the expression of genes involved in
nucleosome maintenance and chromatin architecture.
Materials and Methods
Experimental design
In order to examine the effect of EBNA-1 on the expression of
cellular genes, transcription microarray profiling was performed in
transfected sublines of the EBV negative B-lymphoma line BJAB
that express EBNA-1 either stably [17] or under the control of a
tetracycline regulated promoter [13]. Short-term effects were
monitored within two weeks of EBNA-1 upregulation in BJAB-
tTAE1 while long term effects were monitored in cells that
continuously expressed EBNA-1 for few months, BJAB-tTAE1, or
for several years, BJAB-E1. Non-specific effects were accounted by
comparing the gene expression profiles of untransfected cells or
cells transfected with the empty vector (BJAB-E1/BJAB and
BJAB-tTAE1/BJAB-tTA pairs) or cultured in the presence or
absence of doxycyline (BJAB-tTAE1 +/2 Dox and BJAB-tTA +/2
Dox pairs). Expression profiles were collected from three indepen-
dent experiments where each EBNA-1 +/2 pair was tested in
parallel (Table 1).
Cell cultures and RNA extraction
The cells were grown in RPMI-1640 complete medium
supplemented with penicillin (100 U/ml), streptomycin (0.1 mg/
ml), 10% fetal calf serum and the appropriate selection drugs for
BJAB-E1 (200 mg/ml geneticin - Gibco, Darmstadt, Germany) or
BJAB-tTA/BJAB-tTAE1 (0.5 mg/ml hygromycin - Calbiochem, San
Diego, CA, USA and 0.5 mg/ml puromycin - Sigma-Aldrich, St.
Louis, MO, USA). One mg/ml of doxycycline was added to the
BJAB-tTAE1 culture medium to repress the expression of EBNA-1.
Three aliquots of 10
7 cells were collected from each cell line and
culture condition, and EBNA-1 expression was monitored in Western
blots using the OT1x mouse monoclonal antibody as described [13].
RNA extraction was performed with the RNeasy kit (QIAGENH)
according to the recommended protocol. On-column DNase-I
digestion was performed to ensure the elimination of genomic
DNA and the quality of the RNA was controlled by agarose gel
electrophoresis before preparation for microarray analysis.
Microarray analysis
Gene expression profiling was performed at the Core Facility of
the Institute of Biochemistry, Hannover Medical School, Hann-
over, Germany, using oligonucleotide-based Agilent G4112F 44K
HD arrays (design ID 014850) as recommended by the
manufacturer (Two-Color Microarray-Based Gene Expression
Analysis V5.0.1; Agilent Technologies). RNA preparations were
transcribed into Cy3-labelled (control EBNA-1 negative cells) or
Cy5-labelled (EBNA-1 expressing cells) cRNA, and hybridized
pair wise onto the microarray (Table 1). Data extraction was
performed using the Agilent feature extraction software V9.1.3.1.
The output files from each microarray include the signal
(MedianSignal), standard deviation of the signal (PixSDev),
background (BGMedianSignal), and corrected signal (Processed-
Signal -dye-normalized signal after surrogate algorithm, used for
computation of ratio values) for each channel. From these, a
signal-to-noise ratio for each channel (signal/background) and
relative error (standard deviation of signal/signal) were calculated.
Differences in the expression levels of individual genes were
expressed as ratios reporting the change in intensity between cells
with EBNA-1 (Cy5) and control (Cy3) channels. Ratios and quality
features were calculated using the software Genedata Expressionist
Pro (Genedata AG, Basel, Switzerland). The data has been
deposited in NCBI gene expression data, under accession number
GSE22964.
Quality control and data analysis
The ratio values and quality information including signal-to-
noise ratio and relative error values of each probe were used for
further analysis. Gene filtering and selection of differentially
regulated genes was done using the R package (http://www.
r-project.org). Qualified probes were selected with a signal-to-noise
ratio higher than 2, and relative error lower than 0.25.
Hierarchical clustering was performed to assess the reliability of
the gene expression data in classifying the groups. Differentially
regulated probes were extracted using as cut-off ratio values$1.25
and #0.75 corresponding to 25% change in mRNA level. Samples
derived from three independent experiments were analysed
separately and only genes showing concordant regulation in each
of the experiments were considered as differentially regulated.
Quantitative Real-Time Polymerase Chain Reaction
(qPCR)
The transcription levels of a selected pool of differentially
regulated genes were verified by qPCR. RNA was extracted using
Table 1. Experimental design and RNA labeling.
Experiment group Sample cell line (Cy5) Control cell line (Cy3)
Stable expression BJAB-E1 BJAB
Inducible short-term expression BJAB-tTA-E1 (2Tet) BJAB-tTA-E1 (+Tet)
Inducible long-term expression BJAB-tTA-E1 (2Tet) BJAB-tTA (2Tet)
Tetracycline treatment BJAB-tTA (2Tet) BJAB-tTA (+Tet)
RNA prepared from cells expressing EBNA-1 was labeled with Cy-5, while RNA from control cells with Cy-3. Labeled RNA was then co-hybridized on to individual
microarray to capture the transcriptional changes induced in EBNA-1 expressing cells.
doi:10.1371/journal.pone.0012052.t001
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described [13]. A reaction mix (20ml) containing 20 ng cDNA,
500 nM of the forward and reverse primers for each gene (Table
S1), Kapa SybrFast qPCR Master Mix (10ml, Kapa Biossystems,
Woburn, USA) and water was added to a Fast Optical 96 well
plate (Applied Biosystems, Foster City, USA) and placed into a
7000 Sequence Detection Systems thermocycler (Applied Biosys-
tems). The samples were heated to 50uC for 2 min followed by
95uC for 10 min and 40 cycles of 95uC for 15 sec and 60uC for
1 min were conducted. The signals were analyzed using the ABI
PRISM 7000 software (Applied Biosystems) and the fold increase
was calculated using the DDct method. The GAPDH levels were
similar in parental and stable transfected cell lines (ct value,0.5).
Melting curves were used to assess the specificity of the primers. In
each case, the presence of amplified fragments of the expected size
and absence of non-specific products was confirmed by agarose gel
electrophoresis of the PCR products (data not shown).
Promoter analysis
Promoter analysis was carried out to identify putative
transcriptional targets of EBNA-1. Promoter sequences, identified
as the 59 flanking sequence between 3 kb upstream to 0.5 kb
downstream of the transcription start site of all human genes,
were obtained from the Ensembl database (http://www.ensembl.
org/ release 53). To predict possible EBNA-1 binding sites
sequence patterns and hidden Markov model (HMM) profiles
were generated using 13 non-redundant sequences from the EBV
genome. These included known EBNA-1 binding sites in the
family of repeats (FR) and dyad symmetry (DS) elements of oriP
[5], EBNA-1 binding sites in the Qp promoter [9] and Rep* site
[18]. The derived sequence pattern RRTWRBVYRYRYTDYY
(IUPAC nomenclature where R is purine, Y is pyrimidine W is A
or T, V is not T, D is not C and B is not A) was then used to
search the human promoter database. HMMs were constructed
using the HMMER suite of programs to create a statistical profile
of EBNA-1 binding sequences [19]. The HMM training set was
enlarged to include, in addition to the viral promoters, 60 human
promoter sequences that were found to contain EBNA-1 binding
sites as assessed by chromatin immunoprecipitation (ChIP, 27
promoters) or both ChIP and electrophoretic mobility shift
analysis (EMSA, 33 promoters) [12]. The HMM results were
further categorized based on E-values and raw scores and the
score of the Rep*1 site was used as cut-off. Enrichment of
putative EBNA-1 binding elements in the promoters of the
regulated genes was assessed based on the random occurrence of
such elements in the whole genome. A list of 958 known
transcription regulators (TRs) was obtained from the gene
ontology (GO) category ‘‘transcription regulator activity’’ (GO
Id:0030528).
Analysis of Gene ontology and protein-protein
interaction networks
The GO categories of genes whose expression was differen-
tially regulated were identified using the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID) [20]. The
GO categories with default P-value#0.1 were considered as
significantly affected [21]. Protein-protein interaction networks
were generated using selected sets of genes from the enriched
GO categories and high confidence interaction data were
collected by diverse experimental methods available at the
human protein reference database (HPRD) [22]. The generated
network modules were visualized in the software environment
Cytoscape [23].
Results
Gene expression profile of EBNA-1 expressing cells
The effect of EBNA-1 on the expression of cellular genes was
investigated by transcription profiling of transfected sublines of the
EBV negative B-lymphoma BJAB. In order to discriminate
between early and late EBNA-1 effects, the analysis was performed
in the conditional BJAB-tTAE1 cell line within two weeks of
doxycycline withdrawal, when the expression of EBNA-1 had
reached plateau levels, and after several months of culture in
doxycycline free medium. The latter pattern of gene expression
was compared to that of a stable BJAB-E1 cell line that was kept in
culture for several years. EBNA-1 specific effects were in every
case assessed by comparison with the appropriate EBNA-1
negative control and non-specific effects caused by doxycycline
treatment were accounted for by excluding genes that were
regulated in vector transfected BJAB-tTA. In order to increase the
statistical significance all pair-wise comparisons were performed in
triplicate and only genes showing $25% change in each of the
triplicates were considered as differentially regulated.
An overview of the genes regulated in different conditions of
EBNA-1 expression is shown in Figure 1. A relatively small group
of 319 genes, 192 upregulated and 127 downregulated, were
specifically affected by short-term expression of EBNA-1 in BJAB-
tTAE1 while the number of affected genes was increased by
approximately 10 fold upon long term EBNA-1 expression (5921
genes of which 3015 upregulated and 2906 downregulated) and in
the stable transfectant BJAB-E1 (4383 genes of which 2311
upregulated and 2372 downregulated). Approximately 15% of the
genes regulated upon long-term and stable EBNA-1 expression
were affected in both conditions (837 genes of which 465
upregulated and 372 downregulated). Only 47 genes, 31
upregulated and 16 downregulated, were consistently affected
independently on the time of EBNA-1 expression. A list of these
commonly regulated genes is shown in Table S2. Analysis of the
chromosomal distribution of the differentially regulated transcripts
showed that the altered genes are widely spread on all
Figure 1. Summary of differentially regulated genes in EBNA-1
expressing cells. The numbers of differentially regulated genes in
short-term, long-term and stable EBNA-1 expressing cells are shown.
Arrows indicate up (q) and downregulated (Q) genes with $1.25 fold
change in each of the triplicate experiments. Forty-seven genes are
commonly regulated independently on the time of EBNA-1 expression.
doi:10.1371/journal.pone.0012052.g001
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transcription landscape (Figure S1).
Promoter analysis of the regulated genes
EBNA-1 binds to cellular DNA and was shown to regulate the
transcription of viral and cellular promoters [7,8,13]. In order to
assess whether binding to regulatory DNA sequences may be
involved in the transcriptional effect of EBNA-1, putative
promoter regions located 23000 to +500 bp relative to the
transcription start of regulated genes were searched for the
presence of putative EBNA-1 binding sites using an HMM profile
generated from known EBNA-1 binding sequences. Putative
EBNA-1 binding sites were identified in 4.5% of promoter regions
across the human genome while a significant 2-fold enrichment
was observed among the genes differentially regulated under all
conditions of EBNA-1 expression (Figure 2A). Two or more
binding sites were found in 10–20% of these promoters and four
promoters in this group were previously shown to interact with
EBNA-1 in ChIP-chip assays [12] (Table S3).
To further assess whether the transcriptional effect of EBNA-1
may be broadened through the activation of cellular transcription
regulators we looked for this functional category amongst the
EBNA-1 regulated genes. Genes annotated in the Gene Ontology
(GO) database as ‘‘Transcription regulators’’ (TR) constitute 2.2%
of the human genome and 7.5% of them have promoters
containing putative EBNA-1 binding sites (72 out of 958 gene).
TRs were significantly enriched among the regulated genes in all
conditions of EBNA-1 expression (11, 232 and 182 TRs
differentially regulated in short-term, long-term and stably
EBNA-1 expressing cells, corresponding to 2, 2.4 and 2.6 fold
enrichment, respectively) (Figure 2B). One or more EBNA-1
binding sites were present in the promoters of 4 out of 11 TRs
(36.4%) that were regulated early affected by EBNA-1 induction
(Table S4).
Gene Ontology analysis of the differentially expressed
genes
Given the large discrepancy in the number of genes regulated
upon short- and long-term EBNA-1 expression, we focused our
analysis on the 47 genes that were regularly affected independently
of the time of expression (Figure 1 and Table S2). The most
upregulated gene in this group was the putative transmembrane
phospholipid-transporter ATPase Class II type 9A (ATP9A) and
consistently upregulated were also the tumor necrosis factor
receptor-associated factor 1 (TRAF1), that was earlier shown to be
upregulated in EBV infected cells [24,25]. Ten out of 31
upregulated transcripts were histone H2B variants encoded in
different gene clusters (Table S2). The most downregulated gene
was Membrane Metallo-Endopeptidase (MME), also known as
common acute lymphocytic leukemia antigen, CALLA, CD10 or
NEP, that is highly expressed in mature germinal center B-cells.
Previous studies have shown that downregulation of MME imparts
a growth advantage to various cancers [26].
The GO annotation of the regulated genes was then used to
gain insights on the biological functions that may be modulated by
EBNA-1. This analysis revealed a significant enrichment of GO
terms belonging to the biological processes ‘‘Maintenance of
chromatin’’ and ‘‘Regulation of apoptosis’’ (p-value#0.1, Table 2).
The enrichment in the ‘‘Regulation of Apoptosis’’ category is in
line with earlier reports on the anti-apoptotic property of the EBV
latency I gene expression program [27]. Under ‘‘Molecular
function’’ the commonly affected genes were found in categories
associated with nucleotide binding and phosphatase activity, while
the ‘‘Cellular component’’ category showed enrichment of genes
encoding for proteins associated with chromosomes. The protein
products of the genes regulated in the ‘‘Maintenance of
chromatin’’ category were histone H2B variants, all upregulated,
and the DNA binding proteins SWItch/Sucrose NonFermentable
(SWI/SNF) related, matrix associated, actin dependent regulator
Figure 2. Promoter analysis of differentially expressed genes and genes encoding transcription regulators. A) Histogram showing the
percentage of genes that contain putative EBNA-1 binding sites in their promoters. More than 2-fold enrichment of promoters containing putative
EBNA-1 binding elements was observed in EBNA-1 regulated genes compared to the genome wide random frequency. 28 regulated genes (10
upregulated and 18 downregulated) in short-term expressing cells contain one or more putative EBNA-1 binding sites in their promoters, while upon
long term and stable EBNA-1 expression EBNA-1 binding site was detected in 359 (181 upregulated and 178 downregulated) and 307 (162
upregulated and 145 downregulated) regulated genes respectively. B) Percentages of TRs encoded in the human genome and differentially
expressed in the presence of EBNA-1. Several TRs containing putative EBNA-1 binding sites in their promoter sequences were regulated in EBNA-1
expressing cells. The enrichment was particularly prominent after short-term EBNA-1 expression.
doi:10.1371/journal.pone.0012052.g002
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hSNF5) and immunoglobulin m binding protein 2 (IGHMBP2),
both downregulated. In the ‘‘Regulation of Apoptosis’’ category
were, in addition to TRAF1, non-metastatic cells protein
expressed 5 (NME5), protein C (PROC), and galectin-1
(LGALS1), all upregulated. NME5 belongs to a family of
nucleoside diphosphate kinases (NDKs) that is overexpressed in
cancers [28] and was reported to play a major role in promoting
cell survival in a mouse model [29]. PROC and galectin-1 encode
a vitamin K-dependent serine protease and a b-galactoside-
binding protein that modulate cell-cell and cell-matrix interactions
[30,31]. Additional interacting and catalytic partners of the genes
enriched in ‘‘Biological process’’ were found in the ‘‘Molecular
function’’ category. The ATPases, ATP8B2, ATP9A2, and
microtubule associated serine/threonine kinase family member 4
(MAST4) were upregulated while protein kinase AKT2 (also
known as PRKBB) and Sodium/potassium-transporting ATPase
gamma chain (FXYD2) were downregulated. In addition to the
genes identified in the ‘‘Chromatin maintenance’’ category, the
‘‘Chromosome’’ category enriched under ‘‘Cellular component’’
included NCAPH2, the H2 regulatory subunit of the non-SMC
condensin II complex [32] that was downregulated.
The unexpected enrichment of genes involved in the regulation
of chromatin maintenance prompted us to investigate whether the
effect could be confirmed by conventional qPCR analysis. The
mRNA levels of seven histone H2B variants, SMARCB1,
IGHMBP2, NCAPH2, and NME5 were tested in triplicate
samples of RNA isolated from paired BJAB/BJAB-E1 and
BJAB-tTAE1 cells cultured with or without doxycycline. A good
correlation between the microarray and qPCR data was found for
all the genes tested (Figure 3A), confirming that these genes are
regulated shortly after EBNA-1 expression. In order to assess the
general validity of this observation we turned to publically
available gene expression microarray datasets of EBV negative
BL lines and EBV carrying cell lines expressing latency I where
EBNA-1 is the only detected viral protein (NCBI gene expression
data, GSE2350). Thirty-eight probes corresponding to 27 of the 47
commonly regulated genes (Table S2) were present in these
microarrays. Five of the 27 genes: SMARCB1, IGHMBP2,
NCAPH2, STARD3 and FXYD2 were consistently downregulat-
ed in BLs expressing latency I (KEM-I, Mutu-I and ODH-I)
compared to EBV negative B-lymphoma lines (Ramos, ST486 and
BJAB) (Figure 3B). The consistent downregulation of SMARCB1,
IGHMBP2 and NCAPH2 in both EBNA-1 transfectants and
EBNA-1 expressing BLs strengthen the conclusion that the effect
of EBNA-1 on transcription is likely to involve the activity of
chromatin remodeling complexes.
Protein-protein interaction network analysis
Comparison of the GO categories of the commonly regulated
genes versus genes regulated in short-term, long-term and stable
EBNA-1 expressing cells revealed a progressive expansion of the
number of affected genes in each category depending on the
duration of EBNA-1 expression (Table 3). To assess whether this
expansion involves also chromatin remodeling complexes, genes
annotated in the ‘‘Chromatin maintenance’’ category were
identified in the long-term and stable EBNA-1 expression datasets
and protein interaction data were extracted for the products of 43
genes that were found in both datasets (Table S5). This analysis
revealed the presence of four protein interaction sub-networks
(Figure 4A). One sub-network included, in addition to SMARCB1,
two additional subunits of the SWI/SNF complex, SMARCA4
and SMARCD2 [33]. The second sub-network contained the
CHD3, MBD3 and RBBP4 subunits of the Nucleosome
Remodeling and Deacetylase (NuRD) complex [33,34] and three
known interacting partners. The third cluster was formed by the
CBX8, BMI1 and RNF2 (RING1B) subunits of the Polycomb
repressive complex-1 (PRC1) [35] and their interacting partner
SETDB1. The fourth sub-network included the telomere associ-
ated proteins TNKS and TERF1 [36]. The three chromatin-
remodeling complexes identified by this analysis are involved in
transcriptional repression [33,34,37]. All the affected subunits of
the SWI/SNF and NuRD complexes were downregulated in
EBNA-1 expressing cells while E3 ubiquitin ligases BMI1 and
RNF2 of the PRC1 complex were upregulated. However, the
nucleosome binding subunit CBX8, that anchors the complex to
Table 2. GO categories that are significantly affected in all conditions of EBNA1 expression.
Biological Process Level
No. of
genes P Up-regulated
Down-
regulated
Cellular component organization and
biogenesis
Establishment and/or maintenance of chromatin
architecture
51 2 ,0.001 HIST1H2BJ, HIST1H2BN, HIST1H2BM, HIST3H2BB, HIST1H2BD,
HIST1H2BO, HIST1H2BC, HIST1H2BG, HIST1H2BI, HIST1H2BL
SMARCB1,
IGHMBP2
Regulation of cellular process
Regulation of apoptosis 5 4 0.100 NME5, LGALS1, PROC, TRAF1
Molecular function
Binding
Adenyl nucleotide binding 4 6 0.092 NME5, ATP8B2, ATP9A, MAST4 AKT2, IGHMBP2,
Catalytic activity
Nucleoside-triphosphatase activity 7 4 0.093 ATP8B2, ATP9A FXYD2, IGHMBP2
Cellular component
Non-membrane bound organelle
Chromosome 5 12 ,0.001 HIST1H2BJ, HIST1H2BN, HIST1H2BM, HIST3H2BB, HIST1H2BD,
HIST1H2BO, HIST1H2BC, HIST1H2BG, HIST1H2BI, HIST1H2BL
SMARCB1,
NCAPH2
doi:10.1371/journal.pone.0012052.t002
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downregulated suggesting that also the PRC1 complex may be
functionally inactivated in EBNA-1 expressing cells.
To further explore the observation that chromatin-remodeling
complexes are affected by EBNA-1 expression, we generated a
highly connected protein network by expanding the sub-networks
with their unregulated protein partners. Only unregulated nodes
(proteins) that are connected to two or more regulated partners
were kept to generate a network where all the end nodes are
differentially regulated (Figure 4B). This analysis revealed that the
chromatin remodeling complexes that are regulated by EBNA-1
expression form hubs of a protein interaction network. Thus,
Figure 3. qPCR based validation of selected genes. qPCR analysis was performed on selected differentially expressed genes A). Relative
expression (fold change) of selected genes in inducible and stable EBNA-1 expressing cells compared to controls. The means and standard error of
three independent experiments are shown. B) Genes regulated in EBV positive BLs expressing latency I compared EBV negative BLs. Signal intensities
(au=arbitrary units) obtained from the normalized data. A significant decrease in the mRNA levels of SMARCB1, NCAPH2, IGHMBP2, STARD3 and
FXYD2 is observed in the cells expressing EBV latency type I compared to EBV negative BLs.
doi:10.1371/journal.pone.0012052.g003
Table 3. Expansion of selected GO categories during prolonged EBNA1 expression.
GO category
GO
Level Common Short-term induced Long-term induced Stable
Biological process No. of genesP
No. of
genes P
No. of
genes P
No. of
genes P
Cellular component organization and
biogenesis
2 14 0.062 67 ,0.001 774 ,0.001 622 ,0.001
Establishment and/or maintenance of
chromatin architecture
51 2 ,0.001 24 ,0.001 144 ,0.001 93 0.001
Regulation of cellular process
Regulation of apoptosis 5 4 0.100 14 0.020 146 0.003 137 ,0.001
Molecular function
Binding 2 32 0.023 184 0.001 3017 ,0.001 2544 ,0.001
Adenyl nucleotide binding 4 6 0.092 26 0.094 438 ,0.001 363 ,0.001
Catalytic activity
Nucleoside-triphosphatase activity 6 4 0.094 16 0.011 157 0.009 134 0.020
Cellular component
Non-membrane-bound organelle 2 13 0.029 40 0.075 510 ,0.001 403 0.019
Chromosome 5 12 ,0.001 21 0.001 151 ,0.001 110 ,0.001
doi:10.1371/journal.pone.0012052.t003
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with Histone deacetylases (HDACs) that are required for
transcription repression. Downregulation of both the SWI/SNF
and NuRD complexes is therefore likely to concur in promoting
transcription by preventing the recruitment of HDACs.
Discussion
EBNA-1 is expressed in all EBV-associated malignancies and
may play a role in cell transformation and tumorigenesis [39,40].
Since EBNA-1 does not exert known enzymatic activities, these
effects are likely to be mediated by its well-documented capacity to
regulate transcription [14,15]. Indeed, EBNA-1 binds to both viral
[41,42] and cellular promoters [12] and modulates the activity of
cellular transcription factors [16], but the mechanisms by which
the viral protein reshapes the transcriptional landscape and the
critical cellular targets are largely unknown. We have addressed
this issue by comparing the whole-genome transcription profiles of
cell lines expressing stable or inducible EBNA-1 on the assumption
that common features of the early and late transcriptional
signatures might identify regulatory nodes that could explain the
pleyotropic consequences of EBNA-1 expression.
Our data confirm the previously reported broad effect of stable
or long-term EBNA-1 expression on cellular transcription
(Figure 1). One possible mechanism of this effect is the capacity
of EBNA-1 to directly influence the transcription of at least a
subset of the regulated genes. In support of this possibility, we have
found a statistically significant two fold enrichment in EBNA-1
binding sites by scanning the promoters of the regulated genes
with an HMM profile constructed from known EBNA-1 binding
sequences (Figure 2A). The failure to demonstrate enrichment of
EBNA-1 binding sites in the promoters of genes regulated by
expression of a dominant negative EBNA-1 in the 721 LCL,
reported by Dresang et al. using a similar search algorythm [12], is
likely to be explained by a confounding effect on the transcription
of other EBV latency genes that are also expressed in LCL cells.
Further support to the possibility of a direct effect of EBNA1 on
transcription comes from the observation that known EBNA-1
transcriptional targets, such as FR and Qp promoter in the EBV
genome, contain at least two EBNA-1 binding sites [42,43]
suggesting that this may be a distinctive feature of the regulated
promoters. Our HMM based algorithm identified regulated genes
with promoters containing multiple EBNA-1 binding in both
short- and long-term EBNA-1 expressing cells (Table S3) and the
validity of this prediction is confirmed by the finding that EBNA-1
binds to at least four of the predicted sequences in ChIP-on-chip
assays [12]. However, while these observations strengthen the
assumption of a direct correlation between the binding of EBNA-1
to cellular promoter sequences and the transcriptional response,
the mechanism this regulation remains unclear. In particular, the
failure of EBNA-1 to regulate the activity of several cellular
promoters containing binding sites in luciferase reporter assays
[12] indicates that, when present, the transcriptional effect is
complex and probably dependent on co-factors and on the
chromatin context in which transcription occurs. It is also
important to stress that, in addition to interacting with cellular
Figure 4. Protein interaction networks involving genes with chromatin maintenance function. Networks were derived from the high
confidence protein interaction data of chromatin maintenance genes that were regulated upon long-term EBNA-1 expression. A) Four protein-
interaction sub-networks identified three chromatin-remodeling complexes, SWI/SNF, NuRD and PRC1, that are downregulated and one telomere
associated complex that is upregulated. Upregulated genes are indicated in red and downregulated genes are in green. Genes that are regulated in
both short- and long-term EBNA-1 expression are indicated in bold. B) Network analysis shows that the SWI/SNF and NuRD complexes interact with
key enzymes required for chromatin remodeling such HDACs. Sub-networks are identified by shaded areas. The size of the nodes is proportional to
the number of interactions.
doi:10.1371/journal.pone.0012052.g004
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binds to the small groove of cellular DNA through Gly-Arg-rich
domain that resemble the AT-hook motifs of High Mobility Group
A (HMGA) proteins [44]. HMGA proteins are architectural
transcription factors that regulate the activity of a variety of genes.
While lack direct transcriptional activation capacity, these proteins
regulate gene expression by changing the conformation of DNA
and/or by direct interaction with several transcription factors
(reviewed in [45]). It remains to be seen whether the AT-hook
domain of EBNA-1 could play a role in the regulation of
transcriptional.
In a possible scenario, the transcriptional effect of EBNA-1
could be amplified through the regulation of cellular transcription
factors. Consistent with this possibility, a more than 2-fold
enrichment of genes annotated as transcription regulators (TRs),
including both transcription factors and components of the
transcription machinery, was observed in all conditions of
EBNA-1 expression. This finding is in line with previously
documented capacity of EBNA-1 to activate transcription factors
such as STAT1 and AP-1 [15,16]. Interestingly, TRs containing
EBNA-1 binding sites in their promoters were particularly
enriched among the genes regulated in short-term EBNA-1
expressing cells (Figure 2B). These included for example STAT4,
a member of the STAT family of transcription factors that
regulates cytokine responses and lymphocyte differentiation [46].
While the large number of genes affected in long-term and
stable EBNA-1 expressing cells corroborates the notion that
EBNA-1 activates of a broad transcriptional network, a novel
aspect of this regulation was revealed by the analysis of genes that
are affected shortly after induction of EBNA-1 in the conditional
BJAB transfectant. Only 47 genes were regularly affected in both
short- and long-term EBNA-1 expressing cells suggesting that their
products may be critically required for the phenotypic effects of
EBNA-1. GO analysis of these commonly regulated transcripts
revealed an unexpected enrichment in genes involved in the
maintenance of chromatin architecture. These included several
variants of histone H2B encoded in different gene clusters.
Interestingly, increased protein levels of several of H2B variants
were detected by quantitative mass spectrometry in short-term
EBNA-1 expressing cells (Sompallae et al. unpublished observa-
tion). However, simple analysis Western blot did not revels
significant changes in the steady state levels of the proteins
suggesting that the turnover of H2B variants may be increased.
Indeed, it was recently shown that H2B that is not incorporated
into core histones is highly toxic for the cell and is rapidly
eliminated by proteasome dependent degradation resulting in
virtually unchanged steady state levels of the proteins [47]. Histone
H2B plays a major role in the regulation of transcription via tightly
orchestrated cycles of ubiquitination and deubiquitination [48].
The deubiquitinating enzyme USP7 that binds with high affinity
to EBNA-1 was recently shown to deubiquitinate histone H2B and
contribute thereby to the transcriptional activity of EBNA-1 [49].
Recent findings suggest that excess H2B that is not incorporated
into core histones is highly toxic for the cell and is rapidly
eliminated by proteasome dependent degradation resulting in
virtually unchanged steady state levels of the proteins.
Several subunits of nucleosome organizing complexes were also
present among the commonly regulated genes. Nucleosomes
constitute a potent obstacle for biological processes requiring
access to DNA, such as transcription, DNA replication and repair.
The cellular machinery allowing the access of transcription factors
to their target promoters includes histone acetyltransferases
(HATs) and deacetylases (HDACs) and several chromatin-
remodeling complexes. HATs add acetyl groups to the amino-
terminal tails of histones weakening the interaction with DNA or
the neighboring nucleosomes. HDACs facilitate the compaction of
DNA by reversing histone acetylation while chromatin-remodeling
complexes use the energy of ATP hydrolysis to weaken the
interaction between histone core particles and DNA. At least three
chromatin-remodeling complexes were consistently affected in
EBNA-1 expressing cells. SMARCB1, a core component of all
variants of the SWI/SNF ATPase chromatin remodeling com-
plexes [50,51], was consistently downregulated (Figure 3A). A 2-
fold decrease of SMARCB1 mRNA was also revealed by the
comparison of transcription profiles of EBV negative B-cell lines
and BL lines expressing latency I collected in public databases
(Figure 3B). Hence, SMARCB1 downregulation may be a regular
consequence of EBNA-1 expression. SMARCB1 acts as a tumor
suppressor whose mutations or loss were shown to cause malignant
rhabdoid tumors, an extremely aggressive cancer of early
childhood [52,53] and accumulation of DNA damage [54]. Two
additional subunits of the SWI/SNF complex, SMARCA4 and
SMARCD2, were downregulated in long-term EBNA-1 express-
ing cells, suggesting that the complex may be progressively
inactivated (Figure 4A). Several subunits of the NuRD and PRC1
complexes were also downregulated. The PRC1 complex mediates
the ubiquitination of histones via its E3 ligase subunits [35], while,
similar to SWI/SNF, the NuRD complex uses the energy of ATP
to remodel nucleosome structures via interaction with HDAC
enzymes (Figure 4B).
Collectively, our findings indicate that at least three mechanisms
could contribute to a broad rearrangement of the transcription
landscape in EBNA-1 expressing cells. Direct regulation of a
subset of cellular promoters containing putative EBNA-1 binding
sites and direct or indirect effects on several cellular transcription
factors may initiate a transcription cascade that is greatly amplified
upon prolonged EBNA-1 expression. In addition, an epigenetic
reorganization of the cellular transcriptional milieu may occur
shortly after EBNA-1 expression through the regulation of several
molecular complexes that control chromatin architecture. This
could in turn open the access to transcription factors and promote
the wide-ranging effects on gene expression induced by EBNA-1.
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